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3-phosphoglycerate dehydrogenase (PHGDH) deficiency is a disorder of L-serine biosynthesis that is characterized
by congenital microcephaly, psychomotor retardation, and seizures. To investigate the molecular basis for this
disorder, the PHGDH mRNA sequence was characterized, and six patients from four families were analyzed for
sequence variations. Five patients from three different families were homozygous for a single nucleotide substitution
predicted to change valine at position 490 to methionine. The sixth patient was homozygous for a valine to
methionine substitution at position 425; both mutations are located in the carboxyterminal part of PHGDH. In
vitro expression of these mutant proteins resulted in significant reduction of PHGDH enzyme activities. RNA-blot
analysis indicated abundant expression of PHGDH in adult and fetal brain tissue. Taken together with the severe
neurological impairment in our patients, the data presented in this paper suggest an important role for PHGDH
activity and L-serine biosynthesis in the metabolism, development, and function of the central nervous system.
Introduction
L-serine is a key intermediate in cellular metabolism. It
serves as a precursor for the synthesis of proteins,
membrane lipids, and the neuromodulators glycine and
D-serine. Its metabolism is tightly associated with for-
mation of other important compounds, such as folates,
cysteine, and methionine (Snell 1984). In addition to
acquisition by dietary intake, L-serine may be supplied
by de novo synthesis from glucose. In cells of the CNS,
de novo biosynthesis may supply a significant part of
the required L-serine, since efficient delivery of L-serine
to neuronal tissue is prevented by the blood-brain barrier
(Smith et al. 1987; Boado et al. 1999). L-serine is syn-
thesized from glucose via 3-phosphoglycerate by a num-
ber of consecutive enzymatic steps. 3-phosphoglycerate
dehydrogenase (PHGDH; EC 1.1.1.95) catalyzes the first
committed step in the biosynthesis of L-serine—the con-
version of 3-phosphoglycerate into 3-phosphohydroxy-
pyruvate, which is subsequently metabolized to L-serine
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via 3-phosphoserine. The product of these reactions,
L-serine, may be converted into glycine by serine hy-
droxymethyl transferases (SHMTs). Methylenetetrahy-
drofolate, an important intermediate in the one-carbon-
atom metabolism as a donor of methylgroups, is formed
in this reaction (Snell 1986). Thus, L-serine plays an
important role in the formation of nucleotides for the
synthesis of purines and pyrimidines (Daly and Aprison
1974). Consistent with this concept, the flux through
this pathway is markedly increased by up-regulation of
PHGDH and SHMTs, when cell proliferation demands
high nucleotide-precursor synthesis rates (Snell and We-
ber 1986; Snell et al. 1987, 1988). The catabolism of
L-serine comprises multiple reactions, which may take
place in different cellular organelles and show consid-
erable tissue and species specificity (Narkewicz et al.
1996; Xue et al. 1999a, 1999b). Taken together, L-serine
metabolism is tightly regulated via multiple pathways
according to cellular demands.
The characterization of genetic disorders affecting L-
serine metabolism may provide insight into the specific
role of this amino acid in human physiology. PHGDH
deficiency (MIM 6018153) is characterized biochemi-
cally by reduced plasma and cerebrospinal fluid (CSF)
L-serine concentrations after an overnight fast and clin-
ically by severe neurological impairment (Jaeken et al.
1996). Five patients from three families have now been
described, all presenting with congenital microcephaly
1390 Am. J. Hum. Genet. 67:1389–1399, 2000
Table 1
Positions and Sequences of Oligonucleotide Primers
Primer Sequence (5′r3′) Position
f1 CAGTTACTCTAGCGCGCCAG 88 to 69
f2 GAGGCCAACTCCAGCAATGG 16∼4
f3 TGCCGGAAGATCTTGCAACA 55∼74
f4 CCGCTGATGTCATCAACGCA 179∼198
f5 CAGGATTGGGAGAGAGGTAG 462∼481
f6 TGTGGTGAACTGTGCCCGTG 690∼709
f7 TGGATTGGTCTGGCAGAAGC 994∼1013
f8 GCTTCGGGGAATGCCTCCTG 1250∼1269
f9 CCTGGCCGTGGCCCTGGCAG 1266∼1285
f10 GCGCCCCTTACCAGGCTGTG 1286∼1305
f11 GGCTTGGTCCAAGGCACTAG 1306∼1325
f12 TCAATGGAGCTGTCTTCAGG 1343∼1362
f13 TGGCCTCCTGGCAGAGGCAG 1446∼1465
r1 AGTCCTGCAGCTCCGCTATC 123∼142
r2 GCCTCCAGATCCACATTGTC 241∼260
r3 TCTGGGGAAATGATGGGGTC 522∼541
r4 GTAAACACGTCCAGTGCAGC 769∼788
r5 CTTAGGCAGTTCCCAGCATT 1093∼1112
r6 AGGTCCCTGCGGAGAGGCAC 1369∼1388
r7 TCAGAGGTCTGAGTCCGGAA 1402∼1421
r8 TTAGAAGTGGAACTGGAAGGCTTCAG 1577∼1602
r9 CAGAGGCAGGGACCAGTGAG 1611∼1630
r10 CCCGCGTTCAGCCCAAGAAT 1684∼1703
r11 TTGCTGTACTACAGGGTCAG 1729∼1748
NOTE.—The position of each primer is numbered relative to
the translation start codon. The values “f” and “r” indicate
forward and reverse primers, respectively. Mismatches to intro-
duce restriction endonuclease-sensitive sites in primers f3 and
f11 are underlined.
(Jaeken et al. 1996; de Koning et al. 1998; Pineda et
al. 2000). Psychomotor retardation and severe intrac-
table seizures appeared during the 1st year of life in all
these patients, whereas cataracts, hypogonadism, ad-
duction of the thumbs, megaloblastic anemia, and
thrombocytopenia were variably present. Importantly,
the convulsions in these patients could be ameliorated
by pharmacological supplementation of L-serine,
thereby underscoring the causal relationship between
reduced L-serine concentrations and seizures and pro-
viding an effective potential treatment for the convul-
sions associated with this disorder. Biochemical analysis
in cell lysates of cultured patient skin fibroblasts re-
vealed markedly reduced PHGDH enzyme activities in
all patients with this disorder. However, ∼20% residual
enzyme activity was consistently detected, suggesting
incomplete inhibition or enzymatic redundancy. Other
enzymes in this pathway, 3-phosphoserine amino-
transferase and 3-phosphoserine phosphatase, are un-
affected. Consequently, the disorder was named
“PHGDH deficiency” and classified as an anabolic ami-
noacidopathy (Jaeken et al. 1996).
To characterize PHGDH deficiency at the molecular
level and to provide insight into the nature and origin
of the severe neurofunctional symptoms, we set out to
clone the human PHGDH cDNA and to identify po-
tential mutations leading to reduced PHGDH enzyme
activity.
Material and Methods
Patients and Skin-Derived Fibroblast Cultures
Patients 1 and 2 (from family 1) are Turkish brothers
whose parents are consanguineous. Patient histories and
laboratory investigations have been reported elsewhere
(de Koning et al. 1998). Patient 3 (from family 2) is the
youngest patient described by Jaeken et al. (1996). He
died, at age 5 years, from infectious complications un-
related to PHGDH deficiency. His parents are first cous-
ins. There is no known relationship between families 1
and 2; they originate from the same geographic region
(Konja) in Turkey. Family 3 contains two affected sisters
(patients 4 and 5) with microcephaly, psychomotor re-
tardation, and seizures. Patient 6, a girl whose parents
are a consanguineous Moroccan couple (from family 4),
was recently described elsewhere (Pineda et al. 2000).
Patient skin–derived fibroblasts were cultured in Ham
F-10 media, supplemented with 25 mM HEPES pH 7.4,
L-glutamine, and 10% fetal bovine serum (Life Tech-
nologies) at 37C. Passages 6–12 were used in this study.
RNAwas extracted from fibroblastmonolayers (patients
1–3 and 6) or peripheral blood leukocytes (patients 4
and 5) using Tripure (Roche Molecular Systems). Po-
lyadenylated RNA was isolated using oligo(dT)-coupled
magnetic beads (Dynal). Genomic DNA was prepared
from leukocytes or fibroblasts by digestion with 7 mg/
ml proteinase K in the presence of 1% SDS. Proteins
were precipitated by the addition of NaCl to 1.5 M, and
the DNA was recovered from the supernate by ethanol
precipitation. As controls, RNA and DNA samples from
individuals without neurological and developmental dis-
ease were included.
RNA, Southern Blot Analysis, and Chromosomal
Localization
RNA blot analysis was performed using nitrocellulose
membranes containing poly(A)RNA from different hu-
man tissues (Clontech) or from fibroblast monolayers.
Human genomic DNA was purchased from Roche Mo-
lecular Systems, digested with restriction endonucleases
overnight, electrophoresed on 1% agarose gels, and
transferred to nylon membranes. Blots were analyzed
using [32P]-labeled PHGDH cDNA probes comprising
the complete coding region of PHGDH. For chromo-
somal localization, radiation hybrid mapping was per-
formed with primer set f9–r7 (table 1) and two different
radiation hybrid panels—Stanford G3 (StG3) and Ge-
nebridge 4RH (Gb4RH). PCR conditions were as de-
scribed below. PCR products were resolved by 2% aga-
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rose gel electrophoresis and scored positive, negative, or
ambiguous. Data files were submitted to the Stanford
Human Genome Center and to the Whitehead Institute
for Biomedical Research/MIT Center for Genome Re-
search radiation-hybrid mapping databases 4RH (Cox
et al. 1990; Walter et al. 1994).
Mutation Detection
Single-strand cDNA was synthesized from patient and
control RNA samples (10 mg of fibroblast or leukocyte
total RNA) using oligo(dT) and MMLV–reverse tran-
scriptase (Life Technologies). Overlapping reverse tran-
scription (RT)–PCR products were generated using
primer sets f1–r2, f4–r3, f5–r4, f6–r5, f7–r7, and f12–
r10 (table I) and AmpliTaq DNA polymerase (Roche
Molecular Systems) for 35 cycles (92C for 30 s, 55C
for 30 s, and 72C for 60 s). PCR amplification was
preceded by an initial denaturation for 3 min at 92C
and ended with a 10-min extension at 72C. Formamide
was added to 50%; the samples were denatured at 95C
for 5 min and quickly chilled on ice. Aliquots were ap-
plied to 12.5% polyacrylamide gels (Excel gel; Amer-
sham Pharmacia Biotech). Gels were silver stained to
visualize the DNA (Amersham Pharmacia Biotech). PCR
products were purified by Qiaquick spin columns (Qia-
gen) and analyzed by cycle sequencing using [33P]-labeled
primers and the Amplicycle sequencing kit (Roche Mo-
lecular Systems), followed by 6% polyacrylamide gel
electrophoresis and autoradiography. Sequence data
were analyzed using the PCGENE software program
from IntelliGenetics.
RFLP Analysis
Genomic DNA was subjected to PCR amplification
using PHGDH cDNA-derived primers and the cycling
conditions described above. The assignment of a T or
G at position 75 was determined by PCR with primers
f3 and r1, followed by digestion of the PCR products
with NlaIII, which restricts the 75T allele but not 75G.
Toward this goal, a mismatch was introduced in primer
f3 (table 1). The 1326ArG substitution was analyzed
by seminested PCR, using primers f10–r6 for 15 cycles,
followed by primers f11–r6 for 33 cycles. In combina-
tion with the mismatch in primer f11, the 1326G allele
forms a StuI restriction site. The 1273GrA substitution
in patient 6 was analyzed by BalI digestion after am-
plification with primers f8 and r6. Finally, the 1468A
allele could be specifically detected by PCR amplification
using primers f13–r8 and digestion of the PCR products
with SphI. All samples were incubated with the appro-
priate restriction enzymes for 2 hr at 37C, separated by
6% polyacrylamide gel electrophoresis, and stainedwith
ethidium bromide. Alternatively, digests were analyzed
on Excel gels (Amersham Pharmacia Biotech), and the
DNA was visualized by silver staining.
Expression of PHGDH In Vitro
Fibroblast-derived total RNA (10 mg) from a healthy
individual was reverse transcribed using oligo(dT) and
MMLV reverse transcriptase (Life Technologies). The
complete coding sequence of PHGDH was amplified us-
ing primers f2–r10 and Advantage cDNA polymerase
mix (Clontech) for 33 cycles. An appropriately sized
PCR product was cloned in pCR2.1 (Invitrogen). The
insert of the resulting plasmid (pPHGDH) was se-
quenced to ascertain proper amplification. To construct
plasmids encoding PHGDH that contained the V425M
and V490M mutations, total RNA was utilized from
patients 6 and 4, respectively. RNA was reverse tran-
scribed using primer r11, followed by nested PCR am-
plifications (f5–r10 for 26 cycles and, subsequently,
f6–r9 for 16 cycles). The resulting fragments were di-
gested with ApaI and cloned into pPHGDH, fromwhich
nucleotides 744–1630 were removed by digestion with
ApaI. This resulted in plasmids pPHGDH-425M and
pPHGDH-490M, respectively. The inserts of these plas-
mids were sequenced to ascertain proper replacement
of nucleotides 744–1630 by patient-derived PHGDH
cDNA and the absence of potential PCR-induced se-
quence artifacts. Wild-type and mutant proteins were
subsequently synthesized in a reticulocyte lysate (Pro-
mega) by coupled in vitro transciption translation from
the SP6 promoter in the presence of radiolabeled amino
acids (TRAN [35S]; Amersham Pharmacia Biotech), ac-
cording to the manufacturer’s instructions. Incorpora-
tion of radiolabeled amino acids into newly synthesized
PHGDH was measured by counting trichloroacetic acid
(TCA)–precipitable radioactivity on Whatman 3MM
filters in a scintillation counter. Radioactive PHGDH
was visualized by fluorography after separation on SDS-
PAGE.
Enzyme Assays
The activity of 3PHGDH in fibroblast cell extracts
and in reticulocyte lysates expressing PHGDH cDNA
was measured essentially as described elsewhere (Ach-
ouri et al. 1997). Aliquots of these samples were added
to a mixture containing 25 mM HEPES (pH 7.1), 400
mM KCl, 0.15 mM NADH, 0.1 mM 3-phosphohy-
droxypyruvate (prepared as described in Achouri et al.
[1997]), and 10 mg/ml lactate dehydrogenase. The re-
duction of 3-phosphohydroxypyruvate was measured at
25C by the decrease of NADH absorbance at 340 nm
for 30 min in a spectrophotometer (UVIKON 941; Beck-
man). For kinetic measurements, the 3-phosphohydrox-
ypyruvate concentrations were varied from 0.01 to 0.4
mM. Background enzyme activity values obtained after
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Figure 2 RNA-blot analysis of PHGDH expression. Immobilized poly(A) RNA from adult human peripheral tissues (A), adult CNS
regions (B), and fetal tissues (C) was hybridized with a radiolabeled PHGDH cDNA probe and subjected to autoradiography (upper panels).
The lower panels show hybridization of the same filters with radiolabeled b-actin cDNA. The mobility (in kb) of RNA standards is indicated.
expression of the vector alone were subtracted, and the
resulting data were corrected for TCA-precipitable ra-
dioactivity in the reticulocyte lysates. Data were ana-
lyzed by unpaired student’s t test, and significance was
reached at .P  .01
Results
Cloning and Sequence Analysis of Human PHGDH
cDNA
Initially, a contig consisting of seven overlapping ex-
pressed sequence tags (GenBank accession numbers
T31298, AA114201, T33021, AA313254, AA137039,
AA316052, and W63787) was established by searching
the human EST database using the sequence of a rat
PHGDH cDNA (Achouri et al. 1997). The resulting se-
quence consisted of 1,875 bp. A 102-bp 5′ UTR and a
171-bp 3′ UTR, followed by a poly(A) tail, flanked an
open reading frame of 1,602 nucleotide pairs. A con-
sensus polyadenylation site was found 17 nucleotides
upstream of the 3′ end. To verify this sequence, the com-
plete open reading frame was amplified by RT-PCR, and
the overlapping PCR products were sequenced. The de-
duced amino acid sequence of 533 amino acid residues
was aligned with PHGDH from bacteria and plants as
representatives of two distinct phylogenetic groups (To-
bey and Grant 1986; Ho et al. 1999) and is depicted in
figure 1. The N-terminal domain, which is involved in
targeting of the plant enzyme to plastids, is not identified
in the human and bacterial enzymes. Considerable pri-
mary sequence conservation is observed in PHGDH of
different species, which constitutes 30% amino acid
identity between the human and Escherichia coli en-
zymes and 35% identity between human and Arabi-
dopsis thalania PHGDH (fig. 1). Human and rat
PHGDH displayed 94% amino acid sequence identity
(data not shown). The most homologous domains are
contained within the N-terminal part of the enzyme.
During the course of this work, an independent sequence
representing human PHGDH appeared in GenBank (ac-
cession number AF006043). When compared with the
latter, a single base-pair substitution was noted in our
sequence; a T at position 75 replacing a G. NlaIII-di-
gestion of PCR products from 50 control individuals
suggested that the G at position 75 in GenBank entry
AF006043 represents a sequencing artifact or a rare
polymorphism (results not shown).
Tissue-Specific Expression and Chromosomal
Localization of PHGDH
To determine the tissue-specific expression of human
PHGDH, RNA-blot analysis was performed using
poly(A) RNA isolated from different adult and fetal
human tissues. As shown in figure 2, hybridization of
these blots with PHGDH-specific probes revealed two
transcripts of ∼2.3 and 4.5 kb. Considerable differences
in tissue expression were noted, with high expression in
kidney, liver, muscle, and brain but lower transcript
abundance in other organs. With longer exposure times,
both PHGDH-specific transcripts were present in all
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Figure 3 Mutation analysis in patients 1–5. cDNA fragments were amplified using primer sets f7–r7 (A) or f12–r10 (B) from fibroblast-
or leukocyte-derived total cDNA of the indicated patients and of a healthy control (c), followed by sequencing with primers f8 (A) and f12
(B). The 1326ArG and 1468GrA transitions are indicated by the arrows in A and B, respectively. C and D, Segregation of the PHGDH
1326ArG (C) and 1468GrA (D) mutations. PHGDH fragments were amplified using genomic DNA from the indicated patients, a healthy
control (c), and the parents in family 1, as described in the Material and Methods section. After digestion with StuI (C) or SphI (D), samples
were analyzed by polyacrylamide electrophoresis and stained with ethidium bromide. Molecular size markers (in bp) are indicated. fp father;
m p mother.
lanes, suggesting ubiquitous but variable expression.The
higher-molecular-weight transcript was most prominent
in muscle tissue, whereas the 2.3-kb transcript was more
ubiquitously expressed and was the most prominent
band in different regions of the brain. PHGDH expres-
sion was readily observed in RNA from fetal tissues,
notably also in fetal brain.
To characterize PHGDH at the genomic level, South-
ern blot analysis was performed using PHGDH cDNA
as a probe. Hybridization of restriction endonuclease-
digested genomic DNA revealed a simple pattern con-
sistent with the presence of a single copy gene in the
haploid genome (results not shown). Next, the chro-
mosomal localization of PHGDH was investigated by
mapping on the Gb4RH and StG3 radiation-hybrid pan-
els, as described in the Material and Methods section.
The mapping data on both panels were consistent, and
these experiments resulted in the assignment of PHGDH
to chromosome 1q12. The most closely linked markers
were D1S514 and SHGC-8052, with LOD scores of
∼20.
Mutation Detection
The most straightforward explanation for the molec-
ular defect in our patients with PHGDH deficiency is
that they have mutations in PHGDH. This hypothesis
was investigated by SSCP analysis of overlapping RT-
PCR products, using RNA isolated from cultured patient
skin fibroblasts or leukocytes as templates. Several
changes in electrophoresis patterns were noted when pa-
tient samples were compared with controls, and the cor-
responding patient-derived PCR products were subse-
quently sequenced. Two single-base-pair substitutions
were detected in patients 1, 2, and 3. These patients were
homozygous for a transition 1326ArG, which does not
change the PHGDH amino acid sequence (fig. 3A). To
detect the frequency of 1326G in healthy Turkish con-
trols, control PCR products were analyzed by StuI di-
gestion. Of the 49 samples tested, the 1326G allele was
detected in 19 individuals, including 3 homozygotes (al-
lele frequency 22.5%). In addition, the asymptomatic
mother of patients 1 and 2 is a homozygous carrier of
1326ArG (fig. 3C). These results indicate that this tran-
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Figure 4 Mutation analysis in patient 6. A, cDNA fragments,
amplified using primers f7–r7 from fibroblast-derived total cDNA of
patient 6 and of a healthy control (c), followed by sequencing with
primer f8. The 1273GrA transition is indicated by the arrow. B,
PHGDH fragments, amplified using genomic DNA from patient 6 and
a healthy control (c), as described in theMaterial andMethods section.
After digestion with BalI, to detect the presence of 1273GrA, samples
were analyzed by polyacrylamide electrophoresis and stained with eth-
idium bromide. Molecular size markers (in bp) are indicated.
sition does not cause the disorder and represents a com-
mon coding single-nucleotide polymorphism in the
Turkish population.
Another homozygous single–base-pair substitution
was detected in the PHGDH mRNA of these three pa-
tients, 1468GrA, predicting an amino acid substitution
V490M (fig. 3B). SphI digestion of PCR amplified ge-
nomic DNA confirmed this mutation and revealed that
it was inherited in an autosomal recessive fashion. Using
this assay, the mutation could not be detected in 94
control chromosomes from Turkish controls (fig. 3D and
results not shown). Interestingly, the 1468GrA substi-
tution, but not 1326ArG, was detected in patients 4
and 5 (fig. 3). Because the latter patients are from Eu-
rope, the SphI-RFLP assay was repeated using the DNA
of 50 western-European control individuals. Again, the
1468A allele was not detected in these control samples.
In patient 6, a similar approach led to the identifica-
tion of a homozygous mutation of 1273GrA (V425M)
(fig. 4). This mutation results in the formation of a BalI
restriction site, and restriction analysis of PCR-amplified
genomic DNA indicated that this mutation was also
found in the genomic DNA of this patient, but it could
not be detected in 68 control individuals of the same
ethnic (Moroccan) background. No other mutations
were detected in our patients.
To investigate whether these mutations resulted in re-
duced PHGDHmRNA synthesis rates or stability, north-
ern blot analysis was performed using poly(A) RNA
isolated from patient-derived fibroblast monolayers. In
this analysis, the 2.3-kb PHGDH mRNA species was
abundantly detected, whereas the 4.5-kb transcript was
seen only after overexposure of the blots. No qualitative
or quantitative differences were detected between RNA
samples from patient 1, patient 6, and the control in-
dividual (results not shown).
Expression of Wild-Type and Mutant PHGDH In Vitro
To assess the effect of these mutations on the enzy-
matic activity of PHGDH, the V425M and V490M mu-
tations were introduced into the coding region of
PHGDH by replacing a fragment of the cDNA with
similar fragments obtained from the RNA of patients 6
and 4, respectively. Addition of these constructs and the
plasmid encoding wild-type PHGDH to a reticulocyte
lysate expression system led to the synthesis of proteins
with an apparent molecular mass of ∼58 kDa, in line
with the predicted value of PHGDH (fig. 5A). Addition
of the vector alone did not result in synthesis of radio-
labeled PHGDH, and differences in electrophoretic mo-
bility between the encoded enzymes were not apparent.
The V425M and V490M mutations did not lead to re-
duced protein synthesis in this system, because the in-
corporation of the radio label into these newly synthe-
sized proteins was comparable for each construct used
(fig. 5A). In addition, proteolytic turnover of these en-
zymes was slow and similar for wild-type and mutant
PHGDH (results not shown). We measured the ability
of the in vitro–synthesized proteins to reduce 3-phos-
phohydroxypyruvate to 3-phosphoglycerate. Samples
containing the wild-type PHGDH cDNA exhibited read-
ily detectable enzymatic activity, which was ∼25-fold
higher than that of samples containing the empty vec-
tor. These data indicate that the PHGDH cDNA encodes
a functional protein. Next, the mutant proteins were
expressed, and the obtained enzyme activities were cor-
rected for the amount of enzyme synthesized. These ex-
periments were performed at optimal substrate concen-
trations (0.1 mM phosphohydroxypyruvate), so that our
enzyme activity data represent Vmax (Achouri et al.
1997). Each of the mutant enzymes displayed a mod-
erate but statistically significant reduction in Vmax when
compared with the wild-type enzyme (fig. 5B). The
V425M and V490M mutations resulted in an average
decrease to 58% and 41% of wild-type PHGDHactivity,
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Figure 5 Expression and enzymatic activity of wild-type (wt) and mutant PHGDH. A, Plasmids pPHGDH (lane 2), pPHGDH-425M
(lane 3), and pPHGDH-490M (lane 4), constructed as described in the Material and Methods section. These constructs and the vector alone
(, lane 1) were added to a reticulocyte lysate system in the presence of TRAN[35S] and were incubated for 90 min at 37C. Samples were
analyzed by 12.5% SDS-PAGE and by fluorography. Apparent molecular mass markers (in kDa) are indicated. B, Vmax in reticulocyte lysates
expressing wild-type or mutant PHGDH from the constructs described in A, determined as described in the Material and Methods section.
Data from six independent experiments for each construct are expressed in arbitrary units after correction for TCA-precipitable radioactivity.
The error bar represents the SE, and the asterisks indicate statistical difference from the wild-type enzyme at , using the student’s t-test.P  .01
respectively. To obtain further insight, enzyme kinetics
were determined in the cell-free system after expression
of wild-type and mutant PHGDH. In each case, satu-
ration curves corresponding to mutant PHGDHrevealed
reduced Vmax but were otherwise indistinguishable from
the wild-type enzyme. Both control and mutant enzyme
activities were slightly inhibited by 3-phosphohydroxy-
pyruvate concentrations 10.2 mM (results not shown).
A similar substrate inhibition was observed in purified
chicken-liver PHGDH (results not shown) and in rat
PHGDH (Achouri et al. 1997). Next, we performed ki-
netic experiments in fibroblast lysates from a control
individual and from patients 1 and 6. PHGDH in fibro-
blast extracts displayed approximately identical Km val-
ues for 3-phosphohydroxypyruvate (0.030 mM in con-
trol cells, 0.032 mM in patient 1, and 0.034 mM in
patient 6). Maximal enzyme activities at optimal sub-
strate concentrations were markedly reduced, as de-
scribed elsewhere (Jaeken et al. 1996; de Koning et al.
1998; Pineda et al. 2000). Taken together, with the re-
striction that all enzyme activities were determined in
the nonphysiological direction, these results imply that
both missense mutations V425M and V490M are as-
sociated with a decreased maximal enzyme activity of
the affected PHGDH but that other kinetic parameters
are unchanged.
Discussion
We report two missense mutations in PHGDH that are
associated with a defect in L-serine biosynthesis and lead
to severe developmental and functional impairment of
the brain. These data provide the first molecular genetic
analysis suggesting that the biosynthesis of L-serine is
an important and previously unappreciated metabolic
pathway in the biology of the human CNS.
On the basis of these data, we conclude that the
V425M and V490M mutations in PHGDH cause
PHGDH deficiency. Both mutations segregated with the
clinical and biochemical hallmarks of the disorder and
were not detected in 190 control chromosomes obtained
from healthy individuals with similar ethnic origins. In
addition, assignment of PHGDH to chromosome 1q12
and segregation analysis of V490M in one family clearly
established the autosomal recessive inheritance pattern
of PHGDH deficiency, as has been predicted elsewhere
(Jaeken et al. 1996; de Koning et al. 1998, 1999; Pineda
et al. 2000). Patients 1–3 originated from the same ge-
ographic region and are affected with the same muta-
tion, suggesting a possible founder effect. However, we
propose that 1468GrA (V490M) in patients 4 and 5
arose independently from the same mutation in patients
1–3. This is most clearly demonstrated by the absence
Klomp et al.: PHGDH Mutations Cause L-Serine Deficiency 1397
of the 1326ArG-coding single-nucleotide polymor-
phism in patients 4 and 5 (fig. 3) and is consistent with
the fact that nucleotide 1468 is part of a CpG dinucle-
otide. CpG dinucleotides are well-known mutation hot-
spots (Youssoufian et al. 1988). Additional evidence for
the association of these mutations with the disorder is
provided by functional assays after in vitro expression
of the mutant proteins, showing a significant reduction
in Vmax associated with the 425M and 490M alleles.
Consistent with these data, previous analyses revealed
low PHGDH activity in patient fibroblasts, reduced
concentrations of L-serine in CSF, and marked dimi-
nution of seizure frequency when high doses of oral L-
serine were administered to these patients (Jaeken et al.
1996; de Koning et al. 1998; Pineda et al. 2000). Taken
together with this previous work, our data support the
conclusion that reduced cellular L-serine biosynthesis in
the central nervous tissue due to missense mutations in
PHGDH cause this neurometabolic disorder. The char-
acterization of the molecular defect in PHGDH facili-
tates carrier detection and enables the possibility of pre-
natal molecular diagnosis in these families.
Previous phylogenetic analysis of PHGDH-deduced
amino acid sequences revealed the existence of two dis-
tinct families of PHGDH proteins, represented in figure
1 by the E. coli and A. thalania isoforms, respectively
(Ho et al. 1999). The human and plant PHGDH pro-
teins share 35% identical and 15% similar amino acid
residues, whereas the E. coli and human enzymes are
30% identical and 14% similar. The highest homology
was observed between human and rat PHGDH (94%),
suggesting that human PHGDH forms a homotetramer
and has kinetic properties comparable with the rat en-
zyme (Achouri et al. 1997). When compared with E.
coli PHGDH, the human enzyme contains the consensus
NAD-binding domain characteristic of NAD-dependent
2-hydroxyacid dehydrogenases and a number of con-
served charged residues implicated in the catalyticmech-
anism of the enzyme (Schuller et al. 1995; Grant et al.
1996). These conserved domains and amino acid resi-
dues are located within the N-terminal portion of the
protein, whereas less structural homology is observed
in the C-terminal part. In fact, residues 318–455 of
human PHGDH are missing in the E. coli enzyme, as
well as in the Haemophilus influenzae and Saccharo-
myces cerevisiae orthologs (fig. 1). This suggests that
the C-terminal domain of mammalian PHGDH has less
impact on the enzymatic activity, compared with the N-
terminal domain. Previous experiments based on ex-
pression of a truncated rat PHGDH isoform, of which
the last 209 amino acids were deleted, showed that the
mutant rat enzyme displayed reduced but significant en-
zyme activity, which was subject to salt-sensitive sub-
strate inhibition by 3-phosphohydroxypyruvate, as was
described for the wild-type enzyme (Achouri et al.
1997). It is striking that the two missense mutations
described in this report are both located within this C-
terminal portion of PHGDH (fig. 1). In addition, these
mutations comprise conservative changes, since valine
and methionine are both nonpolar hydrophobic amino
acids. As a result, these conservative changes in a less-
conserved domain of the enzyme are not predicted to
affect the enzymatic activity very drastically. In line with
this concept, fibroblast extracts from patients with these
mutations had a normal Km value and enzyme activity
of ∼20% (Jaeken et al. 1996; de Koning et al. 1998).
When expressed in vitro, PHGDH containing V425M
and V490M mutations displayed Vmax values that were
reduced to ∼50% of control. Thus, in addition to the
lower catalytic turnover, as measured in vitro, the mu-
tations may result in decreased expression of the enzyme
in vivo. Further studies to address this issue that use
specific anti-PHGDH antisera are under way. Taken to-
gether, relatively mild missense mutations in PHGDH
lead to severe impairment of the development and func-
tion of the CNS.
The importance of L-serine biosynthesis in the CNS
is corroborated by our RNA blot experiments, which
indicate that PHGDH mRNA is expressed abundantly
in different regions of the brain and is also prominently
detected in developing neuronal tissue. The finding that
PHGDH mRNA is expressed as two different tran-
scripts of ∼2.3 and 4.5 kb, with variable expression in
different tissues, poses interesting questions regarding
the exact nature of these transcripts, the relative con-
tribution of each transcript to PHGDH protein synthe-
sis, and the tissue and cell-type–specific regulation of
PHGDH gene expression. The necessity for L-serine
biosynthesis in the function and development of the
CNS is apparent in view of the inefficient passage of
neutral amino acids through the blood-brain barrier
(Smith et al. 1987; Boado et al. 1999). As a precursor
of nucleotides, L-serine is important during cell prolif-
eration (Snell and Weber 1986; Snell et al. 1987, 1988),
and, thus, the role of L-serine biosynthesis in relation
to disorders of folate metabolism deserves future atten-
tion. As a building block of proteins and membrane
lipids, L-serine is indispensable, especially for cell
growth, dendritic outgrowth, and myelin formation, as
has been shown in vitro (Savoca et al. 1995; Mitoma
et al. 1998a, 1998b). Importantly, L-serine metabolites
are neuromodulators. Glycine and D-serine, which is
formed directly from L-serine by serine racemase (Wo-
losker et al. 1999a, 1999b), act as direct coagonists of
the NMDA receptor along with glutamate and thus play
a role in synapse refinement, neuronal plasticity, and
exitotoxicity (Johnson and Ascher 1987; Matsui et al.
1995; Nakanishi et al. 1998). Now that the molecular
defect in PHGDH deficiency has been characterized, it
will be possible to generate murine models for this dis-
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order by transgenic approaches. These animals can then
be used to examine the role of L-serine biosynthesis in
the development and function of the CNS and to de-
lineate the pathogenic process leading to psychomotor
delay and convulsions.
Finally, the three major symptoms in these pa-
tients—microcephaly, delay in psychomotor develop-
ment, and convulsions—are not specific for PHGDH
deficiency. Therefore, this and previous work under-
score the importance for critical evaluation of plasma
and CSF L-serine concentrations in the fasted state of
patients presenting with such symptoms of unknown
etiology.
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